APA (7th ed.) Citation

Fjord-Larsen, L., Thougaard, A., Wegener, K. M., Christiansen, J., Larsen, F., Schrøder-Hansen, L. M., . . . Ditlevsen, D. K. (2021, January). Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. mAbs.

Chicago Style (17th ed.) Citation

Fjord-Larsen, Lone, Annemette Thougaard, Karen Malene Wegener, Joan Christiansen, Frank Larsen, Lise Maj Schrøder-Hansen, Marianne Kaarde, and Dorte Kornerup Ditlevsen. "Nonclinical Safety Evaluation, Pharmacokinetics, and Target Engagement of Lu AF82422, a Monoclonal IgG1 Antibody Against Alpha-synuclein in Development for Treatment of Synucleinopathies." MAbs Jan. 2021.

MLA (9th ed.) Citation

Fjord-Larsen, Lone, et al. "Nonclinical Safety Evaluation, Pharmacokinetics, and Target Engagement of Lu AF82422, a Monoclonal IgG1 Antibody Against Alpha-synuclein in Development for Treatment of Synucleinopathies." MAbs, Jan. 2021.